Horizon Therapeutics price target raised to $49 from $36 at Piper Jaffray
December 24, 2019 at 07:29 AM EST
Piper Jaffray analyst David Amsellem raised his price target for Horizon Therapeutics to $49 from $36 and reiterates an Overweight rating on the shares.
